TrialInvestigational new drugs2016

A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.

Manish K Thakur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.